Table 3.
The application of functionalized QDs in tumor-targeted therapy.
| Modification of QDs | Type of Modification | QDs | Types of Cancer | Treatment |
|---|---|---|---|---|
| Functionalized QDs | Lipid and polysaccharide modification | BPQDs@EXO [149] | Bladder cancer | PTT |
| Ce6-HA-GQDs [150] | Non-small-cell carcinoma | PDT | ||
| Protein modification | Peptide E5-modified CdSe/ZnS QDs [151] | Cervical cancer | Ligand-receptor-specific binding | |
| L-cysteine-capped CdSe QDs coupled with methotrexate (MTX) [152] | Oral epidermal carcinoma | Chemotherapy | ||
| IL-13-modified CdSe QDs [153] | Glioma | Ligand-receptor-specific binding | ||
| CdTe/CdS QDs with GP73 [155] | Hepatocarcinoma | Specific binding of antigen to antibody | ||
| BPQDs@DOX@ss-Fe3O4@C-EGFR NPs [86] | Breast cancer | PDT | ||
| Organic polymer modification | CdSe-aza-BODIPY QDs [157] | Cervical cancer | PDT | |
| FA-Cys-CdTe/CdS [158] | Breast cancer | Ligand-receptor-specific binding | ||
| INOP-Mn CdS@ZnS [66] | Breast cancer | Chemotherapy | ||
| mPEG-OAL/N-CQDs [159] | Cervical cancer | Chemotherapy | ||
| TRITC-UCNP-GQDs [160] | Breast cancer | PDT | ||
| BPQDs/PLGA NS [161] | Breast cancer glioma |
PTT | ||
| BP Ve-Ag QDs [162] | Breast cancer | PDT | ||
| siRNA-BPQDs [163] | Ovarian teratocarcinoma | PDT | ||
| Other modification | amino-N-GQDs [139] | Oral epidermal carcinoma | PDT | |
| BPNd [164] | Glioblastoma | PDT |